Format
Sort by
Items per page

Send to

Choose Destination

Best matches for metformin breast cancer:

Search results

Items: 1 to 20 of 544

1.

Metformin as a Therapeutic Target in Endometrial Cancers.

Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, Johnson JM.

Front Oncol. 2018 Aug 28;8:341. doi: 10.3389/fonc.2018.00341. eCollection 2018. Review.

2.

Metformin: Focus on Melanoma.

Jaune E, Rocchi S.

Front Endocrinol (Lausanne). 2018 Aug 21;9:472. doi: 10.3389/fendo.2018.00472. eCollection 2018. Review.

3.

Metabolic Profiles Associated With Metformin Efficacy in Cancer.

Andrzejewski S, Siegel PM, St-Pierre J.

Front Endocrinol (Lausanne). 2018 Aug 21;9:372. doi: 10.3389/fendo.2018.00372. eCollection 2018. Review.

4.

Evaluation of cancer stemness in breast cancer and glioblastoma spheroids in vitro.

Yilmazer A.

3 Biotech. 2018 Sep;8(9):390. doi: 10.1007/s13205-018-1412-y. Epub 2018 Aug 28.

PMID:
30175027
5.

Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.

Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K.

Clin Lung Cancer. 2018 Aug 9. pii: S1525-7304(18)30194-3. doi: 10.1016/j.cllc.2018.07.010. [Epub ahead of print]

PMID:
30172698
6.

Challenges and perspectives in the treatment of diabetes associated breast cancer.

Samuel SM, Varghese E, Varghese S, Büsselberg D.

Cancer Treat Rev. 2018 Aug 10;70:98-111. doi: 10.1016/j.ctrv.2018.08.004. [Epub ahead of print] Review.

7.

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC.

Mol Cell. 2018 Aug 16;71(4):606-620.e7. doi: 10.1016/j.molcel.2018.07.030.

PMID:
30118680
8.

The benefits of adding metformin to tamoxifen to protect the endometrium- a randomized placebo-controlled trial.

Davis SR, Robinson PJ, Jane F, White S, Brown KA, Piessens S, Edwards A, McNeilage J, Woinarski J, Chipman M, Bell RJ.

Clin Endocrinol (Oxf). 2018 Aug 14. doi: 10.1111/cen.13830. [Epub ahead of print]

PMID:
30107043
9.

Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.

Banala VT, Sharma S, Barnwal P, Urandur S, Shukla RP, Ahmad N, Mittapelly N, Pandey G, Dwivedi M, Kalleti N, Mitra K, Rath SK, Trivedi R, Mishra PR.

Adv Healthc Mater. 2018 Aug 13:e1800300. doi: 10.1002/adhm.201800300. [Epub ahead of print]

PMID:
30102470
10.
11.

Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study.

Wu CT, Tsai YT, Lin JG, Fu SL, Lai JN.

Medicine (Baltimore). 2018 Aug;97(31):e11600. doi: 10.1097/MD.0000000000011600.

12.

Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them.

Guo Z, Johnson V, Barrera J, Porras M, Hinojosa D, Hernández I, McGarrah P, Potter DA.

Cancer Metastasis Rev. 2018 Sep;37(2-3):409-423. doi: 10.1007/s10555-018-9749-6. Review.

PMID:
30066055
13.

Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer.

Murff HJ, Roumie CL, Greevy RA, Hackstadt AJ, McGowan LED, Hung AM, Grijalva CG, Griffin MR.

Cancer Causes Control. 2018 Sep;29(9):823-832. doi: 10.1007/s10552-018-1058-4. Epub 2018 Jul 18.

PMID:
30022336
14.

Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.

Athreya AP, Gaglio AJ, Cairns J, Kalari KR, Weinshilboum RM, Wang L, Kalbarczyk ZT, Iyer RK.

IEEE Trans Nanobioscience. 2018 Jul;17(3):251-259. doi: 10.1109/TNB.2018.2851997. Epub 2018 Jul 2.

PMID:
29994716
15.

Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer.

Baglia ML, Cui Y, Zheng T, Yang G, Li H, You M, Xu L, Murff H, Gao YT, Zheng W, Xiang YB, Shu XO.

Cancer Res Treat. 2018 Jul 2. doi: 10.4143/crt.2017.591. [Epub ahead of print]

16.

Gestational diabetes, type II diabetes, and mammographic breast density in a U.S. racially diverse population screened for breast cancer.

Oskar S, Engmann NJ, Azus AR, Tehranifar P.

Cancer Causes Control. 2018 Aug;29(8):731-736. doi: 10.1007/s10552-018-1048-6. Epub 2018 Jun 8.

PMID:
29948515
17.

Ovarian cancer stem cells: A target for oncological therapy.

Markowska A, Sajdak S, Huczyński A, Rehlis S, Markowska J.

Adv Clin Exp Med. 2018 Jul;27(7):1017-1020. doi: 10.17219/acem/73999. Review.

18.

Improved efficacy of mitochondrial disrupting agents upon inhibition of autophagy in a mouse model of BRCA1-deficient breast cancer.

Yeo SK, Paul R, Haas M, Wang C, Guan JL.

Autophagy. 2018;14(7):1214-1225. doi: 10.1080/15548627.2018.1460010. Epub 2018 Jul 20.

PMID:
29938573
19.

Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition.

Chatran M, Pilehvar-Soltanahmadi Y, Dadashpour M, Faramarzi L, Rasouli S, Jafari-Gharabaghlou D, Asbaghi N, Zarghami N.

Drug Res (Stuttg). 2018 Jun 19. doi: 10.1055/a-0631-8046. [Epub ahead of print]

PMID:
29920623
20.

Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.

Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, Edwards DP, MacLean PS, Schedin P.

Breast Cancer Res. 2018 Jun 14;20(1):50. doi: 10.1186/s13058-018-0974-2.

Supplemental Content

Loading ...
Support Center